China's CanSino Biologics Inc said on Wednesday its COVID-19 vaccine was approved in Mexico for emergency use for people of 18 years of age or older.

On Monday, Pakistan said CanSinoBio's vaccine showed 65.7 percent efficacy in preventing symptomatic cases and a 90.98 percent success rate in stopping severe disease in an interim analysis of global trials.